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 Clinical assessment of kidney function is 
central to the practice of medicine. 
Glomerular  ltration rate (GFR) is con-
sidered to be the best index of overall kid-
ney function in health and disease. 
Accurate assessment of GFR levels is 
important for detection, evaluation of the 
severity and progression, and initiation of 
appropriate management for both acute 
and chronic kidney disease. Recent esti-
mates in the United States suggest a prev-
alence of chronic kidney disease (CKD) 
among adults of 13.1 % , and up to 45 % in 
those age 70 or above. 1 Outcomes of CKD 
include not only kidney failure but also 
complications of decreased GFR and 
increased risk for cardiovascular disease. 
Advanced CKD is o/ en complicated by 
anemia or mineral and bone disorders, 
but earlier stages are associated with an 
increased risk for acute kidney injury and 
side effects of medications and proce-
dures. As nephrologists, we are appropri-
ately most concerned with the small 
fraction of patients with advanced kidney 
disease and kidney failure (less than 1 % of 
US adults). However, improving outcomes 
for all patients with CKD requires the 
coordinated e4 orts of nephrologists, other 
specialists, and primary-care physicians. 
Indeed, because of its high prevalence, 
poor outcomes, and high cost, CKD has 
now been recognized as a public-health 
problem, requiring cooperation among 
federal, state, and local governmental and 
private organizations, in addition to phy-
sicians. 2 
 The reporting of estimated GFR 
(eGFR) was identi ed as a key compo-
nent of a public-health strategy for CKD 
in the  rst clinical practice guidelines for 
CKD and has since been endorsed by 
national and international groups. In the 
United States, recent reports show that 
more than 75 % of laboratories now report 
eGFR. 3 In other countries with greater 
coordination of clinical laboratory sys-
tems, these  figures are even higher. 
Focusing on eGFR enables public-health 
campaigns with simple messages such as 
 ‘ Know your number ’ and  ‘ Save your 
kidney function. ’ These messages are 
analogous to those used for hypertension, 
diabetes, or hyperlipidemia, which are 
easily understood by all clinicians, 
patients, and the public. As with other 
public-health initiatives, randomized tri-
als were not available before implementa-
tion of eGFR reporting. ; erefore, studies 
of the impact of eGFR reporting on 
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 The reporting of estimated glomerular filtration rate (eGFR) is a key 
component of a public-health strategy for chronic kidney disease (CKD). 
Jain and colleagues show that eGFR reporting in Ontario increased 
referrals to nephrologists by 23 consults per year, equivalent to 2.9 
additional consults per 100,000 population. In our view, a complete 
assessment requires a broader perspective. Most patients with CKD do 
not require referral to a nephrologist. Improving outcomes requires 
coordinated efforts of all physicians. 
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clinical practice, patient care, and public 
health are important and informative. 
 Jain and colleagues 4 (this issue) focus 
on the impact of eGFR reporting on neph-
rology referrals in Ontario, Canada, from 
January 1999 to September 2007. The 
design and analysis were rigorous. ; e 
authors used the Ontario provincial health 
administrative database, which allows for 
complete ascertainment with little con-
cern for disenrollment. ; ey used sea-
sonal time series modeling to examine 
changes over time. Based on their report, 
the following details emerge. eGFR report-
ing was implemented in all outpatient 
clinical laboratories in January 2006, 
a4 ecting the reporting of approximately 
4.8 million serum creatinine results per 
year for an adult population of 8.9 million 
served by approximately 135 – 140 non-
salaried nephrologists. ; e initiative was 
not accompanied by a province-wide edu-
cational program, but laboratory reports 
did include prompts to relate levels of 
eGFR to CKD. After implementation, 
non-urgent nephrology referrals increased 
from 18,372 (134 per nephrologist) per 
year to 21,805 (156 per nephrologist) per 
year. ; e 23 additional consults per neph-
rologist per year translate to an increase 
in the rate of referral by 2.9 consults per 
100,000 population, with a greater 
increase in women and the elderly. ; e 
authors describe their  ndings as consist-
ent with other reports in the literature and 
conclude that eGFR reporting likely 
caused the increase in nephrology refer-
rals. Limitations of the analysis are that 
the authors were not able to determine the 
clinical characteristics of the patients 
referred, the clinical care provided by the 
nephrologists, nor the patient outcomes. 
 Physician awareness of CKD is low, 5 
and in the United States a substantial 
minority of patients do not see a neph-
rologist until just before the initiation of 
dialysis for chronic kidney failure. Studies 
have documented the association of refer-
ral to nephrologists with improved out-
comes. 6,7 Earlier detection and earlier 
referral are certainly important and 
worthwhile outcomes. However, the 
number of people with earlier stages of 
CKD far outweighs the number with 
see original article on page 318
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management of patients with CKD by 
nephrologists and other health-care pro-
viders. In one large clinical population, 
the average age of patients with CKD was 
approximately 70 years, and death was 
approximately 25 times more common 
than progression to kidney failure. 12 Even 
among patients with CKD stage 4, death 
was three times more common than ini-
tiation of dialysis. ; e recent publication 
of clinical practice guidelines for many of 
the conditions a4 ecting patients with early 
stages of CKD should enable primary-care 
physicians and other specialists to deal 
with many of the routine problems. In our 
view, most patients with CKD do not need 
to be referred to a nephrologist. ; is is 
similar to other common chronic condi-
tions affecting older adults. Not all 
patients with type 2 diabetes are referred 
to an endocrinologist, and not all patients 
with cardiovascular disease are referred to 
a cardiologist. Thus, we need to know 
whether eGFR reporting has led to greater 
adherence by all physicians to these guide-
lines, such as lower blood pressure targets 
in people with CKD, use of medications 
that block the renin – angiotensin system 
in patients with high blood pressure and 
proteinuria, evaluation of complications 
of CKD in patients with CKD stage 3 or 
higher, and appropriate decisions for 
medication selection and imaging proce-
dures as well as dose adjustments. Wyatt 
and colleagues performed such a study at 
the Veterans A4 airs center in the Bronx, 
New York, and demonstrated that despite 
increased recognition of CKD with eGFR 
reporting, the care provided did not 
improve; they concluded that greater edu-
cation coincident with eGFR reporting is 
required for improvement in care. 13 We 
need to know whether eGFR reporting 
has consequences for outcomes of diseases 
other than CKD, such as detection of 
acute kidney injury , medication dose 
adjustment, and monitoring of toxicities 
following initiation of medications. 
 We also need data on the impact of eGFR 
reporting on patient and public awareness 
of CKD and its risk factors, antecedents, and 
outcomes. Management of chronic diseases 
requires patient participation to improve 
outcomes. It is likely that the full bene t of 
eGFR will require educational e4 orts for 
clinicians, patients, and the public. 
 kidney failure, so it is not feasible for 
nephrologists to care for all patients with 
CKD . ; us, Jain and colleagues 4 speculate 
about the appropriateness of the addi-
tional referrals. However, in our view, 
before we can question the appropriate-
ness of referrals, we  rst must develop 
consensus on a care model for CKD that 
describes the role of nephrologists, other 
specialists, and primary-care physicians 
and indications for referral to nephrolo-
gists. ; is task is hampered by the absence 
of a widely used prediction score for pro-
gression to kidney failure. A strategy of 
delaying referral until patients have fur-
ther decline in kidney function is not 
appropriate, as it risks losing the opportu-
nity gained from early detection. Finally, 
we must acknowledge that nephrologists 
have a role in the management of patients, 
even those who do not progress. 
 Other studies have assessed the appro-
priateness of referral following implemen-
tation of eGFR reporting. A report from 
Australia by Noble and colleagues sug-
gested that the number of appropriate and 
inappropriate referrals to nephrologists 
increased a/ er eGFR reporting. 8 Similar 
results were observed by Richards and 
colleagues in the United Kingdom. 9 In the 
latter study, the authors were also able to 
demonstrate a decreased mortality of 
referred patients with CKD stage 4. In 
both analyses, there was no concern that 
the observed higher referral rate would 
exceed nephrology capacity in their 
respective countries. 
 Figure 1 suggests possible indications 
for referral to nephrologists. 10 Impor-
tantly, one indication is that all patients 
with an eGFR less than 30  ml / min per 
1.73  m 2 (CKD stage 4) should be referred. 
A recent analysis of data from the National 
Health and Nutrition Examination Survey 
(NHANES) suggests that approximately 
18.6 % of people with CKD stage 3 would 
also meet these criteria. 11 ; ese data pro-
vide a useful starting point for developing 
care models for CKD. 
 ; e article by Jain and colleagues 4 rep-
resents an excellent  rst step in the evalu-
ation of this large-scale initiative. 
However, for a more complete assessment 
we need data on awareness of CKD by 
primary-care physicians and other spe-
cialists, and appropriate evaluation and 
Evaluation and management of CKD, 
as described in KDOQI CKD Clinical Action Plan
GFR <30 ml/min/1.73 m2
Spot urine total protein-to-creatinine ratio 
>500–1000 mg/g
Increased risk for progression of kidney disease
GFR decline >30% within 4 months without explanation
Hyperkalemia (serum potassium concentration 
>5.5 mEq/l despite treatment)
Resistant hypertension (blood pressure >130/80 mm Hg
despite adherence to a three-drug antihypertensive
regimen that includes a diuretic)
Difficult-to-manage drug complications
Acute presentations of cardiovascular disease
Complex or severe chronic cardiovascular disease 
conditions
Age <18 years
Kidney disease specialist; 
other specialists as appropriate
Kidney disease specialist
Kidney disease specialist
Kidney disease specialist
Kidney disease specialist
Kidney disease specialist
Kidney disease or hypertension 
specialist
Kidney disease or hypertension 
specialist
Cardiovascular disease specialist
Cardiovascular disease specialist
Pediatric kidney disease specialist
 Figure 1  |  Recommendations for referral to specialists for consultation and co-management 
of CKD. KDOQI, Kidney Disease Outcomes Quality Initiative. (Used with permission from the 
National Kidney Foundation. 10 ) 
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 Ongoing initiatives will allow for further 
assessment of this and other public-health 
initiatives to improve the care and out-
comes of people with CKD. 2 A complete 
assessment of eGFR reporting requires a 
broader perspective on CKD than its 
impact on nephrology referral. CKD is no 
longer just about kidney failure, nor is it 
just about us, nephrologists, but includes all 
health-care professionals and the public. 
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 End-stage renal disease (ESRD) is associ-
ated with increased cardiovascular mor-
bidity and mortality, and cardiac disease is 
the leading cause of death among patients 
receiving dialysis (42 % of all-cause mortal-
ity). 1,2 In this context, the steady increase 
in the incidence of ESRD, disproportionate 
to the prevalence of chronic kidney dis-
ease, further feeds the burden of cardio-
vascular complications. Despite the wealth 
of evidence regarding atherosclerotic and 
valvular heart disease in ESRD patients, 
data on cardiac arrhythmias are limited. 2,3 
Notably, atrial  brillation (AF) has recently 
emerged as a prevalent cardiac arrhythmia 
independently associated with ESRD. 3 AF 
in the general population represents a fre-
quent arrhythmia responsible for consid-
erable morbidity and mortality because it 
independently increases the risk of death 
up to 1.9-fold and that of stroke  vefold. 
Its prevalence doubles with each decade of 
age, reaching the level of 9 % at the eighth 
decade of life. Interestingly, recent data 
point to the markedly higher prevalence of 
AF in dialysis patients compared with the 
age-matched general population. 3 – 5 
 ; e prevalence of AF in ESRD patients 
varies considerably among the reported 
studies. 3 Nevertheless, the most recent data 
derived from observational studies indicate 
a prevalence of 13 – 27 % in ESRD patients 
with a mean age between 60 and 67 years. 3,5 
Along the same lines , a recent population-
based cohort study showed a strong and 
graded inverse association between glomer-
ular  ltration rate and the prevalence of AF, 
independent of other vascular risk factors. 6 
 With respect to the incidence of AF in 
ESRD patients, only data on chronic dialy-
sis patients have been published. ; ese data 
indicate an incidence between 1 and 4.1 per 
100 patient-years. 3,5 ; e marked di4 er-
ences between the prevalence and incidence 
rates across the studies can be attributed to 
several factors, such as di4 erent ages of the 
studied populations, and di4 erences in the 
type and documentation of the recorded 
AF episodes, as well as in the time on dialy-
sis and the associated risk factors. 3 
 Vazquez  et al. 7 (this issue) extend previ-
ous observations and report on the preva-
lence and incidence of AF in a cohort of 
patients who started dialysis in their center 
and were followed for a mean period of 2 
years. ; ey also examined the total mortal-
ity and stroke incidence during this time 
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 Atrial fibrillation in end-stage 
renal disease: an emerging 
problem 
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 End -stage renal disease is associated with considerable cardiovascular 
morbidity and mortality. Atrial fibrillation (AF) is prevalent among 
dialysis patients and adversely affects the clinical outcome. Vazquez  et al. 
report an increased prevalence and incidence of AF in patients who 
commence dialysis, and an independent association between arrhythmia 
and mortality risk.  Moreover, they examined clinical and laboratory 
parameters associated with AF. This population study may fuel research 
aiming at the development of novel preventive and treatment strategies. 
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